OF WHAT IS POSSIBLE
Gilead Sciences Hong Kong Limited Room 2603 26th Floor, Hysan Place 500 Hennessy Road Causeway Bay, Hong Kong
BIKTARVY® is a powerful STR that combines the DESCOVY®
backbone with bictegravir, a novel and unboosted INSTI1,2 The image is shown for illustration purpose only. It does not represent the actual size of the tablet. *emtricitabine 200 mg/tenofovir alafenamide 25 mg. BIKTARVY contains TAF, which is active against HBV. Discontinuation of BIKTARVY therapy in patients co-infected with HIV and HBV may be associated with severe exacerbations of hepatitis. Patients co-infected with HIV and HBV who discontinue BIKTARVY should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.1 BIKTARVY is contraindicated with dofetilide, rifampin and St John’s Wort.1,6 §Each BIKTARVY tablet is approximately 15 mm x 8 mm.1 CrCl, creatinine clearance; DDIs, drug-drug interactions; DHHS, Department of Health and Human Services; EACS, European AIDS Clinical Society; FTC, emtricitabine; HBV, hepatitis B virus; HIV, human immunodeficiency virus; IAS, International AIDS Society; INSTI, integrase strand transfer inhibitor; PLHIV, people living with HIV; STR, single-tablet regimen; TAF, tenofovir alafenamide. References: 1. BIKTARVY Hong Kong Prescribing Information (HK-JUN19-EU-MAY19). 2. Deeks ED. Bictegravir/emtricitabine/tenofovir alafenamide: A review in HIV-1 infection. Drugs 2018; 78(17): 1817-28. 3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. (Accessed November 21, 2020). 4. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. Jama 2020; 324(16): 1651-69. 5. The EACS treatment guidelines 10.1 October, 2020. Available at: https://www.eacsociety.org/files/guidelines-10.1_5.pdf (accessed November 21, 2020). 6. Di Perri G. Clinical pharmacology of the single tablet regimen bictegravir/emtricitabine/ tenofovir alafenamide (BIC/FTC/TAF). Infez Med 2019; 27(4): 365-73. BIKTARVY@ Abbreviated Prescribing Information (Version: HK-JUN19-EU-MAY19) Presentation: Each film-coated tablet contains bictegravir sodium equivalent to 50 mg of bictegravir, 200 mg of emtricitabine, and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide. Purplish-brown, capsule-shaped, film-coated tablet debossed with “GSI” on one side and “9883” on the other side of the tablet. Each tablet is approximately 15 mm x 8 mm. Indications: Biktarvy is indicated for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. Dosage: Adults: One tablet to be taken once daily with or without food. Elderly: No dose adjustment is required. Renal impairment: No dose adjustment for patients with estimated creatinine clearance (CrCl)≥ 30mL/min. Not recommended in patients with estimated CrCl below 30 mL/min. Hepatic impairment: No dose adjustment for patients with mild or moderate hepatic impairment (Child-Pugh-Turcotte [CPT] Class A or B). Not recommended in patients with severe hepatic impairment (CPT Class C). Paediatric population: The safety and e cacy in children and adolescents aged less than 18 years not yet been established. Contraindications: Hypersensitivity to the active substances or to any of the excipients. Co-administration with rifampicin and St John’s Wort (Hypericum perforatum). Warnings and Precautions: Patients co-infected with HIV and hepatitis B or C virus: Patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions. Discontinuation of Biktarvy therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis. Patients co-infected with HIV and HBV who discontinue Biktarvy should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. Liver disease: Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered. Weight and metabolic parameters: An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Lipid disorders should be
and Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies. For medical enquiries, please send your request to asiamedinfo@gilead.com or call 800 908 348 (toll-free number). HKBIK0092_v1.0 2/17/2021 DHHS & IAS RECOMMENDED AS AN INITIAL REGIMEN FOR MOST PEOPLE WITH HIV 3,4 EACS RECOMMENDED AS AN INITIAL REGIMEN FOR ART-NAÏVE ADULT HIV-POSITIVE PERSONS 5 Once-Daily small STR§ No Food Requirements Taken Any Time of Day No Booster Active against HBV† HBV No HLA-B 5701 testing required BIKTARVY® is a small STR with once daily dosing1,2 High genetic barrier to resistance HIV Low potential for DDIs‡ Enough said, Trusted care Learn if BIKTARVY® is right for your patients.
BEAUTY
(FTC/TAF)*
managed as clinically appropriate. Mitochondrial dysfunction following exposure in utero: Nucleos(t)ide analogues may impact mitochondrial function to a variable degree. The findings do not a ect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV. Immune Reactivation Syndrome: In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Any inflammatory symptoms should be evaluated and treatment instituted when necessary. Autoimmune disorders have also been reported. Opportunistic infections: Patients should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases. Osteonecrosis: Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiness or diculty in movement. Nephrotoxicity: A potential risk of nephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir alafenamide cannot be excluded. Co-administration of other medicinal products: Biktarvy should be administered at least 2 hours before, or with food 2 hours after antacids containing magnesium and/or aluminium. Biktarvy should be administered at least 2 hours before iron supplements, or taken together with food. Biktarvy should not be co-administered with other antiretroviral medicinal products. Adverse reactions: Most frequently reported adverse reactions were headache, diarrhoea and nausea. Please refer to full prescribing information for full list of adverse reactions. Drug interactions: Interactions between Biktarvy and other medicinal products: St. John’s wort, rifampicin, rifabutin, rifapentine, atazanavir ± cobicistat, boceprevir, azithromycin, clarithromycin, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, magnesium/ aluminiumcontaining antacid suspension, ferrous fumarate, sucralfate, ciclosporin, methadone and metformin. Before prescribing, please consult full prescribing information which is available upon request. Biktarvy, Descovy, Gilead
環節1: PLHIV選擇各種疫苗時的考慮因素 楷和醫療集團 - 林緯遜醫生 1998年畢業於香港中文大學，在公立 醫院內科部門擁有20年的工作經驗。 由2002年開始照顧愛滋病感染者。其 間在2009/10年於加州大學舊金山分 校接受了傳染病及愛滋病醫學的培訓 。 林緯遜醫生在2015年至2019年擔任 香港內科醫學院感染及傳染病專科委 員會課程主任。目前是香港大學醫學 院名譽臨床助理教授和香港中文大學 醫學系名譽副教授，也是香港感染及 傳染病醫學會副會長，香港愛滋病醫 學會和香港愛滋病基金會的董事局成 員。
環節2: PLHIV健康身心生活 - 網絡資訊 香港中文大學 - 巫潔嫻教授 她為香港大學社會科學學士(主修心理 學），及英國諾丁漢大學健康心理學 碩士和哲學博士。她是英國心理學會 特許心理學家及副會士、英國科學委 員會特許科學家、及香港心理學會註 冊心理學家及副會士。巫博士現為香 港愛滋病服務機構聯盟主席，香港吸 煙與健康委員會、國際行為醫學學會 及香港行為健康學會委員。多年來， 巫博士積極開展針對弱勢群體及患病 人群的健康行為及心理健康的研究， 作為項目負責人獲得多項香港政府、 中國內地及國際組織資助的研究，當 中包括：國家自然科學基金、美國 Brown Center for AIDS Research Fund、香港愛滋病信託基金（AIDS Trust Fund）等，發表學術文章140 篇以上。
環節3: 從日常到 PLHIV 身份的心理訴求 臨床心理學家 - 譚嘉恒博士 譚嘉恒博士(Barry)目前是香港一家公 立醫院的臨床心理學家，自 2016 年 起為 HIV 感染者 (PLHIV) 提供服務 。於倫敦大學學院 (UCL) 完成臨床培 訓，該學院具有長久以來為爭取平等 而奮鬥。自 2019 年以來，Barry強 調醫院與社區的關係，一直嘗試通過 心理教育來引起香港當地慈善機構的 工作人員和服務用戶的關注。在他的 治療中，他借鑒了包括 CBT 和心理 動力學理論。在完成了系統治療的培 訓後，他與 PLHIV的工作受到了敘事 治療的很大影響，敘事療法提倡把「 人」與「問題」分開，讓服務對象跳 出主流價值及述說自己的經驗。Barry 經常質疑人們描述和解釋世界的過程 ，繼而邀請 PLHIV 與討論他們自己 和他人關係，特別是挑戰那些已經主 宰他們生活的膠誤及污名化。
環節4: 香港善導會水銀星三號服務及發展 註冊社工 - 王禮賢先生 香港善導會 預防犯罪及健康教育服務 高級經理 香港社會服務聯會 少數族裔服務網絡 委員 香港愛滋病顧問局 愛滋病社區論壇 委員 香港愛滋病服務機構聯盟 委員 服務方向： 少數族裔禁毒、 戒毒及康復服務、 更生人士服務、 健康教育服務、 法院社工服務、 少數族裔精神健康服務
環節5: 愛滋病藥物新世代及考慮 創健醫療 - 方陽醫生 方陽醫生畢業於澳洲奠納什大學，主 修醫學和醫療科學。方醫生畢業後於 香港及澳洲等地執業，其後更獲得澳 洲奠納什大學家庭醫學碩士及悉尼大 學性健康碩士，成為臨床醫學、心理 輔導、性治療及醫療科學界別的專家 。 方醫生積極推廣有關性傳播疾病的預 防、教育及研究工作，並同時擔任多 個不同社福機構的顧問及執委，如「 關注子宮頸癌聯盟」和「關懷愛滋」 。除此之外，方醫生和他的醫療團隊 亦有積極參與性健康相關的研究，與 香港中文大學公共衛生及基層醫療學 院合作，研究包括香港女性性工作者 及同性戀社群的性健康篩查、人類乳 頭瘤病毒 (HPV) 和子宮頸癌普查等。
